Climb Bio (CLYM) Net Income towards Common Stockholders (2020 - 2026)

Climb Bio (CLYM) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$46.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 116.57% year-over-year to -$46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.3 million (down 0.81% YoY) and the FY2025 annual result came in at -$71.3 million, up 30.37% from the prior year.
• Net Income towards Common Stockholders eased to -$46.1 million in Q1 2026, from -$29.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.7 million in Q1 2024 to a low of -$57.7 million in Q2 2024.
• A 5-year average of -$18.0 million and a median of -$13.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders surged 89.04% — and 2025, when it plunged 676.95%.
• Tracing CLYM's Net Income towards Common Stockholders over 5 years: stood at -$7.8 million in 2022, then slumped by 217.3% to -$24.6 million in 2023, then jumped by 64.92% to -$8.6 million in 2024, then plunged by 237.93% to -$29.2 million in 2025, then plunged by 57.73% to -$46.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$46.1 million (Q1 2026), -$29.2 million (Q4 2025), and -$14.5 million (Q3 2025), per Business Quant data.